Life Science Nation Newsletter  |  March 5, 2015  |  Issue 101

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Feb. 25 - Mar. 4)

Seeking Pre-Clinical Stage Novel Platform Therapeutics

Looking Globally for Medical Device, Diagnostic and Healthcare IT Opportunities

Seeking Clinical Stage Therapeutics Throughout Europe
In This Issue

February Mandate Roundup: 79 Investors from 13 Countries

Building Your Brand: The Importance of a Consistent Message

[Video] Healthcare IT Investors Panel at RESI 4


LSN Videos
RESI 4 Recap Video, San Francisco, 2015
RESI 4 Diagnostic Investors Panel
RESI 4 Biotech Family Offices Panel
RESI 4 Medtech Family Offices Panel
 Fundraising Boot Camp 
RESI 4 Clinical Phase I & Phase II Investor Panel
Building Your Brand: The Importance of a Consistent Message
By Michael Quigley, Director of Research, LSN


Scientist-entrepreneurs, often emerging from an insular academic environment, may not think about spending significant time and resources on their communications and marketing materials. Oftentimes these items are thought of only during the last moments of preparation for a fundraising campaign. "My technology speaks for itself, so it doesn't need to be marketed" is the refrain we hear time and time again from entrepreneurs...

February Mandate Roundup: 79 Investors from 13 Countries

By Lucy Parkinson, Senior Research Manager, LSN 


This February, LSN's research staff in Boston has seen not only a lot of snowfall, but also a lot of mandates. We spoke with a total of 79 investors during this short, snowy month. As Figure 1 demonstrates, we had conversations with every type of life science investor that LSN tracks:


These investors are also diverse geographically; although most are based in the U.S., we also spoke to investors in 12 other countries around the world. Fourteen of these investors are based in Asia, a region often untapped by entrepreneurs located outside of it; LSN has discovered through our mandate interviews that most Asia-based life science investors are looking beyond the region for investment opportunities...


[Video] Healthcare IT Investors Panel at RESI 4
By Nono Hu, Senior Manager, Branding & Messaging, LSN

For those who were not able to attend the fourth RESI Conference in January, LSN would like to bring the Healthcare IT Investors panel to you. In this panel, five investors explained their current investment mandates and shed light on the hot topics in the Healthcare IT field:
  • What are the subsectors within healthcare IT that you are most interested in right now? Are there any you are "allergic" to?
  • As you are looking at an investment in the space, what is unique to healthcare IT that you worry about and dig on the hardest as opposed to other investments in other sectors?
  • As entrepreneurs are positioning their companies for investment, is there something like a particular a piece of information, data point or illustration that entrepreneurs can demonstrate that is particularly impressive, or able to distinguish themselves from the crowd?
  • In general, where do you think the trend on valuations is going? Do you think about valuations in this space differently than in other spaces?
  • Aside from Health IT pure plays are you seeing a trend where traditional biotech therapeutic, device or diagnostic companies are utilizing next generation IT or analytics to improve the efficacy or accuracy of their products. How do you view those opportunities as investors?

Healthcare IT Panel
Healthcare IT Investors Panel